Under a tenth of people who could benefit from weight-loss injections like Wegovy have access to them, warns the World Health Organization as it releases its initial recommendations on the medications.
Given more than one billion individuals worldwide currently classified as obese, it is calling for increased and just availability to this class of drugs.
According to forecasts, in excess of 2,000,000,000 are projected to be living with obesity by 2030 if no action is taken.
"The new guidance acknowledges that obesity is a chronic disease that can be managed with comprehensive and ongoing support," said WHO director-general Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and distribution challenges are significant barriers to widespread availability to the injections that can aid individuals in losing considerable body mass, says the body.
Skinny Jab Supply Crisis
Even in the current most optimistic case, the supply of these medications could only cover around 100 million people – under 10% of those who need them, as stated by the health organization.
The guideline encourages countries and companies to increase availability, by strategies like licensing agreements.
The intellectual property rights on semaglutide – the main component of the drug Wegovy – is due to expire in a number of nations in 2026.
How Weight-Loss Jabs Work
The injections imitate a natural hormone to reduce digestion speed, suppress the appetite and increase feelings of fullness so individuals eat less.
People commonly start to lose weight after several weeks of starting on the regular doses.
Studies indicates users may see weight return within a year of halting the treatment, because their normal appetite resume.
Being carrying excess weight elevates your likelihood for experiencing medical conditions, including diabetes, heart disease, brain attack, and specific malignancies.
Excess weight impacts individuals in countries worldwide and was linked to over three and a half million deaths worldwide in 2024, according to the WHO.
